Finally, for NSCLC-NOS 2.5% of cases (45% with KRAS) could be eligible for novel/emerging targeted treatments, in addition to the 11.2% of cases eligible for standard EGFR or ALK targeted therapy. Here, ALK is linked to non-small cell lung carcinoma.